Towards immunotherapeutic drugs and vaccines against multiple sclerosis

  1. Maria Katsara1,2,
  2. John Matsoukas2,
  3. George Deraos2,
  4. Vasso Apostolopoulos1,*

Article first published online: 16 JUL 2008

DOI: 10.1111/j.1745-7270.2008.00444.x

Issue

Acta Biochimica et Biophysica Sinica

Acta Biochimica et Biophysica Sinica

Volume 40, Issue 7, pages 636–642, July 2008

Additional Information

How to Cite

Katsara, M., Matsoukas, J., Deraos, G. and Apostolopoulos, V. (2008), Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochimica et Biophysica Sinica, 40: 636–642. doi: 10.1111/j.1745-7270.2008.00444.x

Author Information

  1. 1

    Burnet Institute, Austin Campus, Immunology and Vaccine Laboratory, Studley Road, Heidelberg, Victoria 3084, Australia

  2. 2

    Department of Chemistry, Section of Organic Chemistry, Biochemistry, and Natural Products, University of Patras, Patras 26500, Greece

* *Corresponding author: Tel, 613-92870666; Fax, 613-92870600; E-mail, vasso@burnet.edu.au

Publication History

  1. Issue published online: 16 JUL 2008
  2. Article first published online: 16 JUL 2008
  3. Received: May 10, 2008 Accepted: May 17, 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (181K)

Keywords:

  • multiple sclerosis;
  • MS treatment;
  • immuno-suppressive drugs;
  • immunomodulatory drugs;
  • MS clinical trials;
  • peptides;
  • altered peptide ligand

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. Numerous treatment options are available to MS patients; however, these options need to be improved. Herein, we review the current drugs and therapeutic approaches available to MS patients, preclinical trial interventions and recent animal model studies for the potential therapy of MS. Since the current treatment of MS remains elusive and is limited, animal studies and clinical research offers an optimistic outlook.

Get PDF (181K)